Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine + cytarabine + DaunoXome dose-escalation study in pediatric relapsed/refractory AML
NL-OMON22399Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML), sponsored by Erasmus MC. Primary endpoint: Recommended clofarabine dose. Started Aug 2009; status: active, not recruiting.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON22399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22399.